Intelgenx Technologies Corp Investor Relations Material

IntelGenx Technologies Corporation is a drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006 and INT0033/2012 (INT0027/2011), an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer's disease; INT0027A2019 to treat opioid addition; INT0010/2006 and INT0036/2013 (INT0048/2020) for treatment of neuropathic pain or nausea in cancer patients undergoing chemotherapy; and INT0048A2021 and INT0049A2022, both based on palmitoylethanolamide.